IDH1 and cholangiocarcinoma: In support of the recent developments in targeted therapies, in August 2021, the FDA approved ivosidenib as a targeted therapy for adult patients with unresectable locally advanced or metastatic CCA with a mutation in the IDH1 gene detected by an FDA-approved diagnostic test [21].